

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 September 2022 (01.09.2022)



(10) International Publication Number
WO 2022/179528 A1

(51) International Patent Classification:

C07D 405/04 (2006.01) *C07D 413/04* (2006.01)
C07D 405/14 (2006.01) *C07D 401/14* (2006.01)
C07D 409/04 (2006.01) *A61K 31/4164* (2006.01)
C07D 403/04 (2006.01) *A61P 35/00* (2006.01)
C07D 417/04 (2006.01)

(21) International Application Number:

PCT/CN2022/077477

(22) International Filing Date:

23 February 2022 (23.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/077706

24 February 2021 (24.02.2021) CN

PCT/CN2021/142622

29 December 2021 (29.12.2021) CN

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(71) Applicant: **INSILICO MEDICINE IP LIMITED**
[CN/CN]; 26th Floor, Three Exchange Square, 8 Connaught Place Central, Hong Kong (CN).

(72) Inventors: **ZAVORONKOV, Aleksandr**; Unit 307A, Core Building 1, No. 1 Science Park East Avenue, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong (CN). **ALIPER, Aleksandr**; 18, Gureva Str. 4a, Ramenskoye, 140103 (RU). **ALADINSKIY, Vladimir**; 8, W. Fernora Street, 112, Kaliningrad, 236001 (RU). **KUKHARENKO, Andrey**; 122, Bachurinskaya 4c1, Moscow, 108814 (RU).

(74) Agent: **AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE**; Tower B, 21st Fl., Suite 2108, 38 Xueqing Road, Haidian, Beijing 100083 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: ANALOGS FOR THE TREATMENT OF DISEASE

(57) Abstract: Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.

WO 2022/179528 A1